Click on the JSmol tab to take a closer look at how GLP-1 (PDB 6X18), semaglutide (PDB 7KI0), tirzepatide (PDB 7FIM), and orforglipron (PDB 6XOX) are able to stabilize the active form of the GLP-1 receptor, and compare these structures to that of the inactive GLP-1 receptor (PDB 6LN2)
While MASLD affects an estimated 86 million people in the United States, there are currently no approved medications specifically for treating it
For more on this stack, see BPC-157 vs TB-500
Practical Protein Strategy: When appetite is at its lowest (often mid-day during the first weeks of titration), a protein shake can deliver your threshold dose in 150 calories
A 50-unit syringe for doses between 15 and 40 units
Understanding what to expect and when to seek medical attention ensures safe treatment